BioSyent (RX) Earnings Date, Estimates & Call Transcripts → [Webinar] A Deep Dive into Options Volatility: Skew & Relative Value (From OIC) (Ad) Free RX Stock Alerts C$8.60 +0.01 (+0.12%) (As of 10:25 AM ET) Add Compare Share Share EarningsStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades Earnings SummaryUpcoming Earnings DateMay. 16After Market ClosesConfirmedActual EPS (Mar. 13) C$0.12 Missed By -C$0.05 Consensus EPS (Mar. 13) C$0.17 Get BioSyent Earnings AlertsEnter your email address below to receive the latest news and earnings results for RX and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RX Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad OIC[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueJoin us for an exploration of essential volatility concepts in our "Volatility Fundamentals II: Skew & Relative Value" session. OIC® instructor Ken Keating will guide you through important topics that options investors should understand. Click here to register now (5/15 Webinar) BioSyent Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:C$0.47 EPSRX Earnings Date and InformationBioSyent last announced its earnings data on March 13th, 2024. The reported C$0.12 EPS for the quarter, missing the consensus estimate of C$0.17 by C$0.05. The company had revenue of C$8.27 million for the quarter, compared to analysts' expectations of C$8.80 million. BioSyent has generated C$0.53 earnings per share over the last year (C$0.53 diluted earnings per share) and currently has a price-to-earnings ratio of 16.2. BioSyent has confirmed that its next quarterly earnings report will be published on Thursday, May 16th, 2024. Read More BioSyent Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/16/2024Confirmed)------- 3/13/2024Q4 2023C$0.17C$0.12C($0.05)C$0.12C$8.80 millionC$8.27 million11/16/2023Q3 2023C$0.10C$0.20+C$0.10C$0.20C$8.20 millionC$8.87 million8/22/2023Q2 2023C$0.12C$0.12-C$0.12C$7.70 millionC$7.96 million5/26/2023Q1 2023C$0.13C$0.10C($0.03)C$0.10C$7.60 millionC$6.48 million3/21/2023Q4 2022-C$0.09+C$0.09C$0.09C$6.90 millionC$7.46 million11/16/2022Q3 2022C$0.13C$0.12C($0.01)C$0.12C$7.00 millionC$6.79 million Get the Latest News and Ratings for RX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. 8/23/2022Q2 2022C$0.14C$0.10C($0.04)C$0.10C$7.50 millionC$6.64 million5/18/2022Q1 2022C$0.11C$0.13+C$0.02C$0.13C$7.00 millionC$7.04 million3/9/2022Q4 2021C$0.11C$0.15+C$0.04C$0.15C$6.90 millionC$7.22 million11/18/2021Q3 2021C$0.10C$0.13+C$0.03C$0.13C$6.90 millionC$6.69 million8/25/2021Q2 2021C$0.10C$0.08C($0.02)C$0.08C$5.90 millionC$7.29 million5/27/2021Q1 2021C$0.09C$0.13+C$0.04C$0.13C$6.10 millionC$7.42 million BioSyent Earnings - Frequently Asked Questions When is BioSyent's earnings date? BioSyent has confirmed that its next quarterly earnings data will be published on Thursday, May 16th, 2024. Learn more on RX's earnings history. Did BioSyent beat their earnings estimates last quarter? In the previous quarter, BioSyent (CVE:RX) missed the analysts' consensus estimate of C$0.17 by C$0.05 with a reported earnings per share (EPS) of C$0.12. Learn more on analysts' earnings estimate vs. RX's actual earnings. How much revenue does BioSyent generate each year? BioSyent (CVE:RX) has a recorded annual revenue of C$31.59 million. How much profit does BioSyent generate each year? BioSyent (CVE:RX) has a recorded net income of C$6.46 million. RX has generated C$0.53 earnings per share over the last four quarters. What is BioSyent's price-to-earnings ratio? BioSyent (CVE:RX) has a trailing price-to-earnings ratio of 16.21 and a forward price-to-earnings ratio of 18.29. More Earnings Resources from MarketBeat Related Companies: HLS Therapeutics Earnings Date Decibel Cannabis Earnings Date Cipher Pharmaceuticals Earnings Date Organigram Earnings Date Sernova Earnings Date Oncolytics Biotech Earnings Date Spectral Medical Earnings Date Theratechnologies Earnings Date Zentek Earnings Date ProMIS Neurosciences Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Traders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future Outlook This page (CVE:RX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
